Key Word Submission Number(s)

(2R,6R)-hydroxynorketamine P354

(R,S)-ketamine P250, P354, P365, P726

(R,S)-ketamine infusion therapy P335

11β-hydroxylase inhibitor P148

17-β-estradiol P197, P314

22q11 deletion syndrome 51.4, P75, P516, P568, P573

22q11.2 deletion syndrome P487

5-HT2A receptor P360, P459

7T MRS P64, P185, P283, P534

a4b2 nicotinic acetylcholine receptors P673

ABCD study P34, P136, P139, P162, P290

academic performance P139

acetylcholine 1.5, 51, 51.3, P107, P381, P573

acoustic startle response P474

Active Avoidance 56, 56.2, 56.4

Acute and Chronic Stress 34, P14, P86, P278, P483, P747

Acute Stress 31.2, 34.1, 34.4, P15, P66, P445, P630, P642, P666

Acute Traumatic Stress P59, P410

Acyl chain remodeling P300

Adaptive deep brain stimulation P235

addiction 9, 55.1, P56, P586, P643, P649, P670, P675, P723, P738

addiction circuitry P731, P732

Addictions Neuroclinical Assessment P658

ADHD 30, 30.1, 30.2, 44, 44.1, P119, P123, P158, P167, P173, P175, P291, P293, P424, P433, P443

Adjunctive cariprazine P436

Adolescence 21.1, P42, P78, P135, P139, P160, P178, P189, P190, P239, P280, P299, P626, P660

Adolescence- Critical Period 43.1, 57, 57.1, 57.4, P706

Adolescent P168, P705, P723

Adolescent Alcohol P49, P632, P647

Adolescent Alcohol Use P741

Adolescent Anxiety 38, 49.2, P113, P290

Adolescent Brain and Cognitive Development Study P121

Adolescent Brain Cognitive Development study P124, P161, P302

Adolescent Depression 49.2, 57, P165, P252, P290

adolescent development P129

adult hippocampal neurogenesis P9, P382

Adverse childhood events P161, P296

Adverse life experiences P312

affective behavior 40.4, P388

affective components of pain P623

affective instability P32

African American P160, P522

Aggression P94, P101, P341, P390

Aging 14, 14.4, 18.3, P1, P5, P10, P14, P283, P437, P570, P657

Alcohol 50, P4, P444, P621, P626, P627, P631, P641, P646, P654, P655, P666, P672, P684, P692, P694, P710, P715, P721, P729, P730, P736

Alcohol Abstinence P725, P737

Alcohol and substance use disorders P596, P606, P638, P720

Alcohol epigenetic marks P610

Alcohol Sensitivity P686, P691

alcohol use disorder 25.2, 52.4, P182, P588, P613, P622, P629, P630, P645, P651, P656, P667, P671, P678, P679

Alcohol Use Disorder - Treatment 50.3, P608, P614, P625, P643, P669, P681, P688

Alcohol use disorder and drug addiction 25, 34.4, P595

alcohol use disorders 25.3, P154

alcohol withdrawal P71, P612

Allosteric modulator P601

alternative splicing P153

Alzheimer disease P3, P7, P397, P403, P408

Alzheimer’s Disease 12, 42.2, P4, P154

AMPA receptors P306, P565, P569

Amygdala 7.4, 8.1, 21, 21.2, 21.4, 47, 47.2, 47.4, 55, 55.1, 55.2, P51, P62, P66, P85, P94, P104, P108, P120, P272, P291, P293, P307, P539, P630, P632, P654, P730, P736, P752

androgen deprivation 58.2

anhedonia 9.3, 52.3, P47, P176, P240, P244, P267, P330, P344, P356, P389, P478, P649

animal model 1, 1.3, 33.4, 48.1, P748

Animal Models 18.1, 31.2, 34.2, P176, P404, P698

anorexia nervosa P191, P192, P193, P195, P197, P200, P206

Anterior Cingulate Cortex (ACC) P389, P627, P678

Anterior insula-prelimbic pathway P312

Antidepressant 52.2, P240, P298, P344, P355, P409

anti-depressant like action P361

Antidepressants P326, P354, P379

anti-gliadin antibodies (AGA) P546

Antipsychotic 27.1, 53, P298, P489, P530

Antipsychotic drugs 51.2, P488

antipsychotic medication P350

Antipsychotic response P554

antipsychotics 27.3, 51.4, P212, P540, P561

Anxiety 30.3, 49, 52.1, P30, P34, P36, P42, P49, P55, P65, P70, P78, P81, P82, P83, P106, P126, P182, P262, P479, P605, P622, P654

Anxiety & PTSD 7.4, P40, P58

Anxiety and Depression 16.1, 27, 42, P130, P292

Anxiety and stress 31, P86, P725

Anxiety circuitry P86, P113

Anxiety development 38.2, 38.3

anxiety-like behavior P41

anxiety-like phenotype P23

Approach/Avoidance 40.1, P44, P263

Artifical transcription factors P218

associative learning 55.2

Astrocyte 35.1, P4, P211, P266, P500, P599, P612

Astrocyte-Blood vessel interaction P380

astrocyte-neuron interaction 35

astrocytes 18, 18.1, 35.2, P176, P215, P598

Attention P126, P167, P270

Attention Deficit Hyperactivity Disorder P433, P443

attentional bias P31, P55

Auditory fear conditioning 51.1, P63, P574

Auditory hallucinations 51.2, 51.3, 51.4

auditory perception 51, P574

Auditory striatum 51, 51.1, P574

Autism 5.3, 15.1, 33.1, 44, 44.1, 44.4, P109, P114, P116, P151, P439, P546

autism spectrum disorder 33, 33.4, P166, P172, P179, P455, P569

Autism spectrum disorder and related syndromes 5, P129, P131

autism Spectrum Disorders P117, P150, P170, P174

Autoimmune encephalitis P543

autonomic nervous system P57, P91

Aversive Learning 56, 56.2, 56.3, P102

avoidant/restrictive food intake disorder P190

Axon Initial Segment (AIS) P481

Basal Ganglia 31.2, P554, P744

basolateral amygdala 47.1, 55.3, P66, P107, P179, P381, P431, P468, P574, P663

bed nucleus of stria terminalis P51, P84, P647

behavioral economics P649, P699, P709

behavioral flexibility P105, P746

behavioral inhibition system P735

Behavioral Model 30, P201, P407

Behavioral Pharmacology 41.3, P86, P208, P368, P405, P458, P680

Behavioral Phenotyping P653

Behavioral Tasks P18, P433

binge drinking 50.3, P602, P641, P659, P702

Binge eating 39.3, P194, P469

Binge Eating Disorder 39, 39.3, P21, P204

Biology of aging P6, P13, P545

Biomarker P535, P611, P681

Biomarker analysis P299, P403, P436

Biomarkers for Risk Assessment 43.2

Bipolar Disorder P120, P189, P217, P231, P234, P239, P254, P269, P270, P277, P283, P291, P293, P295, P303, P306, P310, P317, P329, P336, P339, P340, P353, P359, P364, P371, P482, P525

Bipolar I & II disorder P373

Blood-Brain-Barrier P374, P666

BNST 25.3, P87, P622, P664

body dissatisfaction P199

Body Dysmorphic Disorder P415

body image disturbance P199

BOLD fMRI signal P277, P418, P631

Borderline Personality Disorder P469

Brain Based Markers for Depression P402

brain connectome 5.4, P40

Brain development 42.1, P133

Brain Insulin Resistance 27, 27.1, 27.4

brain networks P209, P510

Brain nutrient sensing 27.3

brain stimulation 8, 8.3, 19, P208

brain transcriptomics P110

Brain-Based Predictive Modeling P499, P511

Brain-Behavior Relationships 30.4, 46

Brain-mediated mechanisms 27.3

Buprenorphine-Naloxone P615

Ca2+-permeable AMPA- type glutamate receptors P701

calcium imaging P96, P216, P395, P421, P489

cAMP signalling P411, P561

cannabinoid receptor type 1 P727

cannabis P145, P270, P586, P633, P650, P668, P683, P684

cannabis concentrates P684

cannabis use disorder 26.3, P598, P683

cardiovascular function P93

cariprazine P83, P342, P343, P351

Cell adhesion molecules P652

Cell- and Circuit-selectivity P589, P639

central amygdala P595, P600, P721

central nucleus of the amygdala P318

c-Fos-expressing ensembles P753

chemogenetics 18.1, 44.4, P103, P151

Child abuse and neglect P430

child and adolescent psychiatry P136

Childhood Adversity P11, P69, P651

childhood maltreatment P54, P636

Childhood trauma P46, P90, P145, P281, P321, P429

Childhood-onset schizophrenia P528, P529

Children and Adolescents P55, P143, P146, P171, P371

Cholesterol biosynthesis P4

cholinergic system P10, P596

Chronic corticosterone P268

chronic pain P59, P180, P688, P689, P715

Chronic social and non-social stress P253

chronic social defeat P373

chronic social defeat stress P112, P357

Chronic social stress P319, P380

chronic stress P211, P375, P391

Chronic unpredictable mild stress P376, P378

chronic unpredictable stress P222, P224

Chronic variable stress P221

circadian rhythm P254, P401, P482

circuit optogenetics P51, P111, P751

Circuitry-based approach 55.2, P659

Circulating cell-free mitochondrial DNA P223

Clinical Development P491

clinical high risk for psychosis 43.3, P534, P549, P563, P576

Clinical high-risk of psychosis P509, P515

Clinical Neurobiology P457

clinical neuroimaging research 37, P308

clinical outcome prediction P193, P335

clinical psychopharmacology P553

Clinical trial P25, P117, P119, P239, P400, P424, P494, P495, P614, P615

Clinical Trial Design 45, P450

Clinical Trial Methodology 8.2, P334

Clinical Trial Rating Methods P333

clinical trials methodology P28

Closed-loop stimulation P263

CNS Clinical Trials P298, P450, P491

cocaine 1.4, P611, P642, P663, P676, P701

cocaine addiction P592, P750, P752, P753

cocaine and opioid use disorders P584

cocaine self-administration P738, P747, P750

cocaine self-administration and reinstatement 55.3

cocaine sex differences P587, P716, P747

cocaine use disorder P443, P636, P644, P696, P706

Cognition 5.1, 18, 18.1, 24, 24.1, 24.4, 52.4, 53, P6, P124, P185, P246, P402, P408, P452, P496, P706, P712

Cognitive / behavioral flexibility P224, P500

cognitive and affective neuroscience 28

Cognitive biomarkers P229

Cognitive Control Cetwork P419

cognitive control network 21.2, 31.1

Cognitive Decline 24.2, 58.3

Cognitive dysfunction P571, P605

cognitive flexibility 7.1, P133

cognitive function P348, P532

Cognitive Functioning P499, P529

cognitive impairment 58, P222

Cognitive impairment associated with schizophrenia 24.3, 24.4, P503, P557

Cognitive Impariment 14, 58.2, P503, P564

Cognitive Neuroscience 58.3, P43

cognitive reappraisal P53

Cognitive remediation P242

cognitive training P119, P447, P452

Complement component 4 P523

compulsive drug intake P610

Computational Cognitive Neuroscience 30.2

computational ethology P330

Computational Genomics 35.3

Computational Methods P438, P514

computational modeling 3, 30.1, 30.3, 46, 56.1, P195, P284, P646

computational models of decision-making 16.4, P194

Computational Neuroscience 24.3, 30.4, P39, P513, P643

computational psychiatry 30.2, 30.3, 56.1, P56, P194, P287, P521

Concurrent Disorders P670

conditioned fear memory P377

conditioned inhibition of fear P96

conditioned place preference P592, P716

Connectivity gradients P35, P100, P687

Consummatory behavior P702

Continuous performance task P43

coordinated specialty care P551

copy number variants P110, P529

copy number variation P517

Correctional Psychiatry P670

cortical development P150

cortical thickness P54, P155

Cortico-striatal-thalamo-cortical Circuits 35.1

corticotropin releasing factor P609

Corticotropin-Releasing Hormone P94, P376

Cortisol P13, P38, P43, P311

Cortisol response to stress P245

COVID-19 38.3, 48.3, P91, P402, P503

COVID-19 pandemic P38, P58, P121, P262, P435

c-reactive protein P544, P545

cue-induced craving 26.2, P625, P634, P678, P688

D1 dopamine receptors 40.3

D2 dopamine and 5HT2A serotonin antagonists P356

D2 dopamine antagonists 27.1

D2 dopamine receptor P661

DBS 13.3, 31, 31.3, 31.4, P418

Decision Making 55.2, P195, P388, P390, P431, P468, P638, P712

deep brain stimulation 13, 13.1, 49, 49.4

Default mode network (DMN) 26.1, P258, P418, P576

defensive and motivated behaviors P107

delay discounting P441, P501

delta9-tetrahydrocannabinol P652

Depression 17, 27.4, 30.2, 30.3, 41.4, 42.2, 42.3, 52.4, P24, P60, P224, P230, P233, P245, P248, P250, P257, P260, P262, P274, P275, P276, P281, P294, P296, P297, P300, P308, P313, P316, P320, P322, P325, P326, P327, P328, P343, P345, P359, P368, P369, P372, P374, P375, P376, P380

Depression and Anxiety 30, P227

Depression model P204, P337, P366

Depression subtypes P228, P229

Development 18.4, 49, P124

developmental origins 54, P8

Developmental Psychopathology 38.4, P128

Developmental Sensitive Period P133

developmental trajectories P154

Developmental trajectory P113, P115

Developmental transcriptome P153

Diffusion Tensor Imaging (DTI) P567

diffusion tractography 31.4, P305

Diffusion Weighted Imaging P52

digital assessment 11, P167

Digital phenotyping 12, 16, 16.2, 16.4, P329, P333

digital therapeutic P129, P167

dimensional psychopathology P187

dimensions of psychosis 7.3

discriminative conditioning P96, P100

Diversity and Inclusion P169

DNA Methylation P54, P60, P77, P217, P301, P656

Dopamine 1.4, 7.3, 27, 27.2, 31.3, 40.3, 50.1, 50.2, 51, 51.1, 51.2, 51.3, 51.4, 55, 55.1, 55.2, 55.3, 56, 56.3, 56.4, 57.1, 57.2, P5, P19, P83, P105, P149, P203, P206, P207, P394, P432, P466, P542, P556, P559, P561, P574, P589, P593, P603, P609, P661, P687, P739, P740, P746, P748

Dopamine (D2, D3) receptors P356, P488

dopamine D2 receptors P561

dopamine D3 receptors P719

Dopamine D4 receptor P707

dopamine transporter 31.3

Dopaminergic neurons P489

Dorsal anterior cingulate cortex P669

Dorsal striatum P203, P411, P590, P690, P738, P741

dorsolateral prefrontal cortex (DLPFC) P64, P153, P255, P534, P617

Dorsomedial striatum P573, P582

dose-response relations P323

drift diffusion model P286

Drug choice paradigm P676

Drug Development P399, P704

Drug Discovery - new approaches P76, P363, P379, P503

drug discrimination 50.3, P691

Drug Relapse 34.1, P606, P699

drug self-administration P709, P735

drug-drug interaction P709

Dual orexin receptor antagonist (DORA) P615

Dual Orexin Receptor Antagonists P581, P696

Dynamic Causal Modeling P258, P415

dynamic functional connectivity P687

early brain development 38.2, P140

Early life adversity 14.3, P144, P434

early life infection P155

Early life stress (ELS) P69, P111, P112, P115, P160, P161, P164, P177, P178, P385, P587, P663

early onset psychosis P122, P528

Early Phase Drug Development P408

early psychosis 24.1, P305, P499, P501, P535, P536

early-life adversity 9.3, P9, P163, P318, P385

Early-life experience P142

Eating disorders 3, P190, P191, P194, P197, P202, P206

ecological momentary assessment P32, P35, P37, P168, P333, P451, P689

Education and Training 20

EEG biomarkers 8, P130, P228, P252, P334, P450, P557

EEG connectivity P154, P267

EEG electrophysiology P352, P448

EEG/ERP electrophysiology P191, P274

Effective Connectivity P30, P415

Efference copy/corollary discharge P502

effort based decision making task P389

Effort-Cost Decision-Making P620

electric field modeling P325

electroconvulsive therapy 17, 17.4, P266, P288, P325, P332, P382, P465

Electroencephalography (EEG) 43.1, P130, P169, P232, P267, P456, P502, P567, P570, P571, P572, P611

Electronic cigarette (e-cigarette) P586, P722

Electronic Health Record 45

electrophysiology P220, P391, P485, P487, P706

Emergency Department P410

Emotion Circuitry 9, P39, P97

Emotion regulation P248, P279

Emotional dysregulation P275, P469

Emotional regulation 21.1, P57, P271

Emotional stress P369, P628

endocannabinoid system P117, P188, P594, P747

Endocannabinoids 34.1, 47.3, 56, 56.4, P46, P50, P90, P380, P559, P626, P628, P715, P727, P732

ENIGMA Working Group P519

environmental risk factors 5, 29

epigenetic age acceleration P11, P54

Epigenetic Modification 1, P595

epigenetic regulation P606

Epigenetics P1, P115, P213, P455, P592, P656, P657

epilepsy 33.1, P396, P406

Esketamine nasal spray P236

excitation-inhibition balance P151

excitatory and inhibitory imbalance hypothesis 44.4

Excitatory Synapses P76, P422

executive function 30, 58.1, P652

exploration-exploitation tradeoff P432

explore-exploit dilemma P6, P284

Expression Polygenic Risk Score P300

extended-access self-administration P701

Extended-release naltrexone P616

Externalizing behavior 14.2

Extinction learning 41.1, P627

extracellular matrix P211

Extracellular vesicles 15.1, 15.2

Extrapyramidal symptoms P351

extrasynaptic glutamate P220

eye tracking P170, P473, P679

F-18 PET Imaging 38.2, P12

Facial emotion processing 27.4, P55, P255, P456, P629

facial expression analysis P265

familial risk of bipolar disorder P371

family history of alcohol use disorder P658

fast scan cyclic voltammetry P591

Fatty acid amide hydrolase P304, P594

Fear P51, P87, P104, P108

Fear conditioning 7, 23, 47.1, P46, P78, P97, P100, P107, P369, P642

Fear conditioning and extinction 47.2, P85, P103

fear-potentiated startle P36, P89

feeding behavior 50, P205

Fentanyl 22, 22.1, 22.2, 22.3, P583, P624, P640, P665, P692, P695, P709

fetal alcohol spectrum disorder P401

Fetal Brain Development 14.2, P477

fiber photometry 56.3, P149

first episode psychosis P513, P551, P555

first-episode psychosis P550

fMRI Effective Connectivity P629

fMRI Functional Connectivity P32, P125, P293

focused ultrasound 13.3, P260, P365

formal thought disorder P512, P513

fragile X syndrome P159, P169

frequency optimization P322

frontotemporal dementia P18

functional and structural neuroimaging 5, 58, P63

functional brain networks P124

functional connectivity P111, P200, P260, P554

functional data analysis P465

functional magnetic resonance spectroscopy P533

Functional MRI (fMRI) 8.1, 9.3, 26.3, 26.4, 38.1, 44.4, P6, P30, P45, P47, P48, P55, P65, P68, P99, P132, P143, P173, P190, P192, P248, P261, P384, P428, P430, P449, P454, P457, P504, P508, P614, P621, P623, P625, P627, P633, P644, P648, P661, P671, P678

functional neuroimaging 40.1, P157, P275, P280, P457, P494

G protein-coupled receptors P601

GABA-A receptors P324, P368

GABAergic interneurons 7.1

gamma oscillations P365, P518

gamma, theta, delta P448, P464

Gamma-band auditory steady-state response (ASSR) P567

Gene co-expression networks 6.1, P297, P482

Gene environment interaction P164

gene expression 6, 58.1, P150, P471, P587

Gene-by-sex interaction P189

Gene-environment interaction P253

generalized anxiety disorder P39, P79, P99

Genetic Association Analyses P523

Genetic association study P156, P525, P653

Genetic variation P198, P436

Genetically encoded sensor P411

Genome-wide association studies P522

GLP-1 receptor agonist 39

Glucagon-like Peptide-1 39.1, 39.3

glucocorticoid receptor P222

glucocorticoid receptor gene P177

Glucocorticoid signaling P312

Glucocorticoids 34, P22, P266, P604

GluN2A recepter subunit P219

glutamate P64, P216, P278, P345, P353, P377, P458

glutamate GABA 43.1, 57.1

glutamate GABA co-release P273

glutamatergic synapses P548

goal-directed behaviors 35.2, P745

GRIN-related disorders P395

Group 2 Innate lymphoid cells P23

growth mixture modeling P313

Gut Microbiome 14.1, P147, P315, P316, P478, P667

GWAS P416, P436, P441, P524, P532

habenula 49.2, P273, P596

Habenula and Periventricular Thalamus 49, 49.1

Habit Reversal Therapy P413

heart rate variability P44, P93

heroin self-administration P639, P711

High Density Sleep EEG P563

high-throughput screening P76, P114

hippocampal connectivity P387, P576

Hippocampal neurogenesis P210

Hippocampal-prefrontal P37

Hippocampus 7, 7.4, P1, P35, P62, P108, P266, P297, P434, P448, P494, P516, P539, P619, P749

Hippocampus Shrinking P409

hippocampus-mPFC pathway P101

Hispanic/Latinos 42, 42.2, P326, P651

histone deacetylases P455

HIV and Inflammation P321, P586

HIV-Associated Neurocognitive Disorder P181, P185

Homeostatic Plasticity 33.1

hormonal contraceptive use P476

HPA axis dysregulation P312

Human Genetics P440, P657

Human Laboratory Study P618

Human Neuroimaging 3, 8.2, 10, 19, 25.3, 40, 49, P40, P65, P145, P184, P189, P325, P455, P549, P620, P622, P637

human pluripotent stem cells P487

human postmortem brain tissue P110

Huntington’s Disease P398

hypothalamus 23.2, P196, P445

imaging genetics P302, P440

Immune Biomarkers P301, P547

impulsivity 30.1, P34, P125, P441

in vivo calcium imaging 41.1, 51.2, 56.2, P98, P377, P743

in vivo electrophysiology 7.3

In vivo fiber photometry 47.3, 55, P19, P111, P179, P203, P363, P411, P593, P638

incentive motivation P251

incentive salience 9.2, P658

incubation of cocaine craving P593

Incubation of drug craving 34, 34.2

incubation of oxycodone craving P590

Independent Component Analysis 16.2, P673

individual differences 9.2, P731

individual variation P635

Induced pluripotent stem cells (iPSCs) P484, P485, P527, P578

Infant Brain 5.3, 38, 38.1, P186

Infant Emotionality 38, 38.3, P186

inflammation 14.1, 14.2, P4, P50, P92, P217, P247, P322, P327, P370, P371, P544, P545, P564, P580, P665

Inflammatory Markers P274, P311

Inhibitory control 57.4, P34, P128, P270, P419, P621

inhibitory interneuron 52.1, P585

Inhibitory interneurons 47.3

Intergenerational transmission of trauma P54

interleaved TMS/fMRI P272

Intermittent Access self-administration 1.4

internalizing disorders P32, P130, P138

interpeduncular nucleus P106, P596

intestinal microbiome P172

intracranial EEG P272, P448

intracranial self-stimulation P722

intravenous drug self-administration P583

intrinsic motivation P504

IV- Ketamine 17.4, 31.1, P25, P230, P450

kappa opioid receptor P714, P745

Kappa Opioid Receptor Antagonist P240

Ketamine 31, P70, P246, P332, P337, P345, P357, P370, P379

Ketamine/esketamine 17, P288

Ketogenic diet P269, P697

kynurenine metabolism P579

Lactate-to-Pyruvate ratio P235

Laser Capture Microdissection P486

Late-life Depression P223

Lateral Habenula 49.4, P201, P729

Learning 55, P104, P206, P271

learning and memory P433, P452

learning generalization P447, P641

Learning Health System P555

light-sheet microscopy P734

local field potentials P208

longitudinal multimodal imaging P41

longitudinal study 38.2, P186, P634, P648

long-term 17.2, P237, P343

M1 and M4 Muscarinic Receptors P493

machine learning P130, P161, P193, P232, P288, P306, P328, P332, P335, P537

machine learning classification P208, P330

Machine learning clustering P171, P256, P282, P289

Magnetic Resonance Imaging 9, P340, P509

magnetic resonance spectroscopy P64, P506

magnetoencephalography 43.4, P246, P258

Major depression P266, P333

Major Depressive Disorder (MDD) 21.2, 21.3, 49.4, P22, P210, P211, P214, P221, P225, P226, P227, P228, P231, P234, P237, P238, P240, P242, P243, P244, P249, P264, P267, P268, P285, P289, P295, P299, P304, P306, P307, P323, P331, P332, P334, P342, P343, P350, P355, P362, P373, P383, P423, P436, P547, P569

Master Observational Trial 45

maternal immune activation 48.1, P148, P477

maternal mental health P140, P430

Matrix Metalloproteinases P598

MDMA 41, 41.1, 41.2, 41.3, 41.4, P29, P456

Mechanistic Clinical Trial P248

medial entorhinal cortex P7

Medial Orbitofrontal Cortex 56

Medial Prefrontal Cortex 18.1, 34.1, 41.1, P100, P103, P105, P121, P133, P149, P259, P378, P395, P396, P602, P747

medio-dorsal thalamus P534

Medium Spiny Neuron P603, P748

Memory 18.2, 42.2, P1, P8, P16, P35, P434

Memory and Learning P393, P461

memory reconsolidation P752

Mendelian Randomization P524

Mental Health and Health Disparities 42, P171

Mental health disorders P152

Mesocorticolimbic system P127

mesolimbic circuitry 56.3

mesolimbic reward circuitry P314

metabotropic glutamate receptor P605

Metabotropic glutamate receptor 2 (mGluR2) P382

Methamphetamine Self-Administration 50.1, P605

methylphenidate P207, P687

Microbiome 14.2, 14.4, P166

Microbiota-gut-brain axis 14, P316

microcircuit processing 47.3

microglia 18, 18.3, 18.5, 25.2, 40.4, P73, P114, P176, P222, P318, P319, P517, P645, P662, P668, P718

mild cognitive impairment due to AD P181, P242

Mild Traumatic Brain Injury P410, P442

mismatch negativity P95, P568

Mitochondria P2, P213, P223, P378, P409, P417, P575

mitochondrial DNA copy numbers P177, P373

mixed features P231, P234

Mobile technology 16.3, 42.3, P167

Monetary reward P48, P184

monoclonal antibodies P608

mood and anxiety disorders P358

mood disorders 9, 10, P58, P236, P273, P486

Morphine sensitivity P253, P697

mother-child dyads P33, P38

motivation 57.2, P271, P573, P740

Motor Evoked Potentials P541

Mouse and monkey models P453

Mouse Circuit Dissection 51

Mouse models P180, P391, P607, P668

MRI P307, P423, P444, P516, P539, P742

Mu opioid receptor P251, P355, P582, P589, P693, P713

Multimodal Neuroimaging P289, P402, P536

Multimodality neuroimaging 43.4

Multi-omics P62, P319, P681

multivariate pattern analysis P325

mu-opioid receptor agonist P704

Muscarinic receptor agonist P492

N,N-Dimethyltryptamine (DMT) P80

natural language processing (NLP) P328, P512, P513, P514

naturalistic drug cues P634

Negative Affect P260, P506, P632, P647

negative reinforcement P19

Negative Symptoms 24.1, P122, P490, P491, P501, P508, P509, P544, P571

neighborhood resources P132

Neighborhood Socioeconomic Deprivation P146

network based statistic (NBS) P636

network control theory P285

network neuroscience 43, 43.2, P30

Neural circuit and animal behavior 55.4, P390

neural circuits 31, P66, P98, P385

Neural connectivity 44.4, P262

neural progenitor cells 15.2

Neuroactive Steroids P474

neuroanatomy 39, 39.1, P440

neurobiological subtypes 44

Neurocognitive assessment 12, 30.2

neurocognitive function 58

Neurodegenerative Disease P17, P400